ArticleJournal of inflammation research2025
Mild Chronic Colitis Exacerbates Intracerebral Inflammation in Mice with Parkinson's Disease Through LRRK2-Mediated Regulation of NF-κB Activation and Inhibition of Nrf2.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Colonic LRRK2 expression is increased in Crohn's disease but not in Parkinson's disease and idiopathic RBD.Acta neuropathologica · 2026Article
- Sugiol Alleviates Cerebral Ischemia/Reperfusion Injury in the Early Phase Involving the LRRK2/NF-κB Pathway.Cell biochemistry and biophysics · 2026Article
- Nrf2 Activators in Parkinson's Disease: Modulating Mitophagy and Regulating Cuproptosis.Molecular neurobiology · 2026Review
- Unveiling Shared Genetic Architectures and Causality: Intestinal Diseases and Neurological Diseases.Brain and behavior · 2026Article
- Chronic gut inflammation differentially modulates mitochondrial and antioxidant transcriptional programs in limbic brain structures.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Inflammatory bowel disease (IBD) is a known risk factor for Parkinson's disease (PD). Leucine-rich repeat kinase 2 (LRRK2), a protein associated with both disease, regulates inflammation in the colon and brain. However, the precise mechanism by which LRRK2 mediates the crosstalk between intestinal inflammation and PD neuropathology remains unclear. This study aims to elucidate how LRRK2 mediates the inflammatory response in both the gut and brain. Methods: A dual-hit (DSS+MPTP) mouse model was established to induce IBD and PD, along with separate single DSS-induced colitis and MPTP-induced PD models. LRRK2 expression was analyzed in the colon and striatum. Intestinal barrier integrity (ZO-1, Occludin), dopaminergic neuron loss and inflammation (TH, Iba-1 staining in SNpc/striatum), NF-κB and Nrf2 pathways activity, and levels of inflammatory cytokines (TNF-α, IL1-β, IL-6 and IL-10) in the colon and striatum was assessed. Results: In the colon, LRRK2 expression was significantly increased in all experimental groups compared to the control, with the highest levels observed in the dual-hit group. The elevated LRRK2 expression correlated with the reduction in ZO-1 and Occludin levels and an increase in inflammatory cytokines IL1-β and TNF-α. A similar pattern of LRRK2 expression was observed in the brain. The dual-hit group exhibited increased Iba-1 expression and a significant loss of dopaminergic neurons. Furthermore, the upregulation of LRRK2 was associated with NF-κB activation and Nrf2 inhibition in the brain. Conclusion: Mild chronic colitis induced by DSS may exacerbate brain inflammation in MPTP-induced PD mice by upregulating LRRK2 expression, leading to NF-κB activation and Nrf2 inhibition. We propose that LRRK2 may play a regulatory role in the NF- κB/Nrf2 interplay in PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.